loading page

Splenectomy as an effective treatment for macrothrombocytopenia in Takenouchi-Kosaki syndrome
  • +6
  • Shio Yamano,
  • Akihiro Iguchi ,
  • Kotaro Ishikawa,
  • Atsushi Sakamoto,
  • Toru Uchiyama,
  • Kumiko Yanagi,
  • Tadashi Kaname,
  • Shinji Kunishima,
  • Akira Ishiguro
Shio Yamano
National Center for Child Health and Development

Corresponding Author:yamano-s@ncchd.go.jp

Author Profile
Akihiro Iguchi
National Center for Child Health and Development
Author Profile
Kotaro Ishikawa
National Center for Child Health and Development
Author Profile
Atsushi Sakamoto
National Center for Child Health and Development
Author Profile
Toru Uchiyama
National Research Institute for Child Health and Development
Author Profile
Kumiko Yanagi
National Center for Child Health and Development
Author Profile
Tadashi Kaname
National Center for Child Health and Development
Author Profile
Shinji Kunishima
Gifu University of Medical Science
Author Profile
Akira Ishiguro
National Center for Child Health and Development
Author Profile

Abstract

Takenouchi-Kosaki syndrome (TKS) exhibits clinical features represented by macrothrombocytopenia, developmental delay, dysmorphic facial features, and deafness. There is little information on the treatment for macrothrombocytopenia in TKS. Splenectomy has been a contraindication for inherited thrombocytopenia. In the case of autoimmune haemolytic anaemia (AIHA) with TKS that we previously reported, AIHA initially resolved with prednisolone; however, it gradually became resistant to drug therapy. We performed splenectomy, and post-operatively, both anaemia and macrothrombocytopenia improved. This is a novel effect of splenectomy for thrombocytopenia in TKS, which suggests that splenectomy could be a treatment option for thrombocytopenia in TKS.
02 Dec 2022Published in International Journal of Hematology. 10.1007/s12185-022-03491-w